Bull/Bear Index 48.0/100
→
싸이토젠-휴믹, ‘항암제 내성 극복·전이 억제’ 전임상 CTC 분석 통합 솔루션 론칭
Key takeaway
"싸이토젠-휴믹, ‘항암제 내성 극복·전이 억제’ 전임상 CTC 분석 통합 솔루션 론칭" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 10 out of 100. Reported by Maeil Business on February 10, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Get the next high-impact catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 49.3%.
Join Telegram channel
or scan with phone →